Probiotic Preventive Efficacy Study Service in Animal Models

We maintain access to commonly used challenge organisms for established models. If your study requires a specific, less common isolate, we will review sourcing, characterization, import or transfer requirements, and whether client provision is appropriate before finalizing the protocol.

We provide study protocols, traceable datasets, analysis outputs, and technical reports that can support your broader documentation strategy. The exact study design and reporting package are scoped to the intended product category, development stage, and jurisdiction discussed with your team.

A preventive study begins probiotic exposure before the disease challenge or induction event and defines outcomes around avoiding, delaying, or reducing disease. Therapeutic activity requires a design in which intervention begins after challenge or after prespecified disease evidence appears.

Selection considers expected colonization or functional onset, product route, dosing frequency, target species, disease kinetics, available pilot data, and the intended real-world use pattern. More than one window may be compared when timing is a key development uncertainty.

Yes. When baseline microbial composition or target-taxon abundance is likely to influence challenge response, sampling and prespecified balancing or stratification can be incorporated. Feasibility depends on assay turnaround, cohort size, and the model schedule.

Useful inputs include strain identity, viable count and purity information, formulation and excipients, available safety and efficacy data, storage and preparation instructions, proposed dose, target species or indication, expected use pattern, and the decision the study must support.